EGFR-TKIs的治疗药物监测研究进展

Research Progress in Therapeutic Drug Monitoring of EGFR-TKIs

表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKIs)在非小细胞肺癌(non-small cell lung cancer,NSCLC)治疗中发挥了重要作用,越来越多的研究表明,对该类药物开展治疗药物监测(therapeutic drug monitoring,TDM)进行个体化剂量调整可以优化临床治疗结果。笔者聚焦于此类药物的药物浓度-效应关系、药动学差异及其影响因素等内容,综述近十年来对EGFR-TKIs的TDM的研究现状和相关问题,为EGFR-TKIs用于治疗NSCLC过程中充分利用TDM优化患者用药提供参考。

Epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs),play an important role in the treatment of non-small cell lung cancer(NSCLC),and more and more studies indicate that therapeutic drug monitoring for these drugs can be useful.This paper focuses on the concentration-effect relationship,pharmacokinetic variability and influencing factors of these drugs,and reviews the research status and related issues on TDM of EGFR-TKIs in recent ten years,so as to provide reference for further promoting the application of TDM in the treatment of NSCLC with EGFR-TKIs and optimizing medication use.